نتایج جستجو برای: regorafenib

تعداد نتایج: 831  

Journal: :Liver cancer 2017
M Kudo

Locoregional therapy is the primary treatment for hepatocellular carcinoma (HCC). Sorafenib was approved as a first-line systemic therapy for advanced HCC with associated extrahepatic spread and/or vascular invasion in 2007. However, there are several limitations associated with sorafenib therapy. To overcome these problems, various clinical trials have been conducted to develop additional mole...

2016

Locoregional therapy is the primary treatment for hepatocellular carcinoma (HCC). Sorafenib was approved as a first-line systemic therapy for advanced HCC with associated extrahepatic spread and/or vascular invasion in 2007. However, there are several limitations associated with sorafenib therapy. To overcome these problems, various clinical trials have been conducted to develop additional mole...

Journal: :Gastrointestinal stromal tumor 2022

Background and Objective: Targeting KIT PDGFRA with traditional tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib regorafenib has revolutionized the treatment prognosis of patients diagnosed locally advanced metastatic gastrointestinal stromal tumors (GISTs) but resistance to those therapies represents a major challenge in management progression disease after third line. In this rev...

Journal: :Annals of Oncology 2023

Regorafenib is considered the standard third-line therapy of mCRC, which has demonstrated a survival benefit over placebo in randomized trials. Another, less proven approach to re-challenge previously effective treatment regimens. We compared factors associated with longer PFS use regorafenib and chemotherapy mCRC. analyzed prospective database pts mCRC from two clinics Russian Federation. cond...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Andrew P Garner Joseph M Gozgit Rana Anjum Sadanand Vodala Alexa Schrock Tianjun Zhou Cesar Serrano Grant Eilers Meijun Zhu Julia Ketzer Scott Wardwell Yaoyu Ning Youngchul Song Anna Kohlmann Frank Wang Tim Clackson Michael C Heinrich Jonathan A Fletcher Sebastian Bauer Victor M Rivera

PURPOSE KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST). Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop (exons 17/18) being particularly problematic. Here, we explore the KIT-inhibitory activity of pona...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید